Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL755537 | 0.76 | ALDH1A1 (0.46) | TSHRCASP1ESR2CHRNA7 | |
| SCHEMBL13656499 | 0.76 | TSHR (0.40) | TSHRCASP1ESR2CHRNA7 | |
| SCHEMBL5189811 | 0.74 | TSHR (0.39) | TSHRCASP1ESR2 | |
| SCHEMBL6277805 | 0.74 | TSHR (0.39) | TSHRCASP1ESR2 | |
| SCHEMBL18727714 | 0.72 | — | — | |
| SCHEMBL13656503 | 0.71 | TSHR (0.50) | TSHRCASP1ESR2CHRNA7 | |
| SCHEMBL24229293 | 0.67 | ESR2 (0.32) | ESR2 | |
| SCHEMBL569231 | 0.67 | TRIM24 (0.33) | ESR2 | |
| SCHEMBL2041552 | 0.67 | — | — | |
| SCHEMBL8227442 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680336-A1 | AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | Ventus Therapeutics U.S., Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20260007684-A1 | AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U S INC (US) | 2026-01-08 | — | — | US | disclosed |
| WO-2024196788-A1 | AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2024-09-26 | — | — | WO | disclosed |
| US-20190055204-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2019-02-21 | — | — | US | disclosed |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-8772301-B2 | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2011075699-A2 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2011-06-23 | — | — | WO | disclosed |
| US-7649199-B2 | N-type semiconductor materials in thin film transistors and electronic devices | EASTMAN KODAK COMPANY (US) | 2010-01-19 | — | — | US | disclosed |
| US-7649199-B2 | N-type semiconductor materials in thin film transistors and electronic devices | EASTMAN KODAK COMPANY (US) | 2010-01-19 | — | — | US | disclosed |
| US-20090256137-A1 | N-TYPE SEMICONDUCTOR MATERIALS IN THIN FILM TRANSISTORS AND ELECTRONIC DEVICES | BANK OF AMERICA, N.A., AS AGENT | 2009-10-15 | — | — | US | disclosed |
| US-20090256137-A1 | N-TYPE SEMICONDUCTOR MATERIALS IN THIN FILM TRANSISTORS AND ELECTRONIC DEVICES | BANK OF AMERICA, N.A., AS AGENT | 2009-10-15 | — | — | US | disclosed |
| WO-2009126203-A1 | N-TYPE SEMICONDUCTOR MATERIALS IN THIN FILM TRANSISTORS | EASTMAN KODAK COMPANY (US) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | GRM5, GRM2, GRM1 | TSHR 1410/4885CASP1 3997/4885ESR2 403/4885 |
| US-20190055204-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | TSHR 1410/4885CASP1 3997/4885ESR2 403/4885 |
| US-20260007684-A1 | AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | NOD1, NLRP3, NOD2 | TSHR 3171/4885CASP1 5/4885ESR2 1609/4885 |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | TSHR 1410/4885CASP1 3997/4885ESR2 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.